NASDAQ:ATYR Atyr PHARMA (ATYR) Stock Price, News & Analysis $1.88 +0.13 (+7.43%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.75▼$1.9850-Day Range$1.64▼$2.2352-Week Range$1.08▼$2.50Volume772,323 shsAverage Volume466,296 shsMarket Capitalization$129.74 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends Get Atyr PHARMA alerts: Email Address Atyr PHARMA MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside963.8% Upside$20.00 Price TargetShort InterestHealthy0.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.15Based on 6 Articles This WeekInsider TradingAcquiring Shares$172,369 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.94) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.26 out of 5 starsMedical Sector475th out of 909 stocksBiological Products, Except Diagnostic Industry67th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingAtyr PHARMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtyr PHARMA has only been the subject of 3 research reports in the past 90 days.Read more about Atyr PHARMA's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.47% of the float of Atyr PHARMA has been sold short.Short Interest Ratio / Days to CoverAtyr PHARMA has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atyr PHARMA has recently increased by 28.16%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtyr PHARMA does not currently pay a dividend.Dividend GrowthAtyr PHARMA does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATYR. Previous Next 1.7 News and Social Media Coverage News SentimentAtyr PHARMA has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Atyr PHARMA this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for ATYR on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Atyr PHARMA to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atyr PHARMA insiders have bought more of their company's stock than they have sold. Specifically, they have bought $172,369.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of Atyr PHARMA is held by insiders.Percentage Held by Institutions61.72% of the stock of Atyr PHARMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atyr PHARMA's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Atyr PHARMA are expected to decrease in the coming year, from ($0.94) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atyr PHARMA is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atyr PHARMA is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtyr PHARMA has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atyr PHARMA's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable ProsperityHere’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees need to hear. It's shocking to me that more people aren't wise to this, as they are leaving money on the table from stocks they have a strong belief in. I call it "The Cash Flow Trade", and my team is going to teach you how and when to execute it in this free live event.CLICK HERE TO RSVP About Atyr PHARMA Stock (NASDAQ:ATYR)aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.Read More ATYR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATYR Stock News HeadlinesSeptember 6 at 6:23 AM | americanbankingnews.comAtyr PHARMA (NASDAQ:ATYR) Now Covered by Jefferies Financial GroupSeptember 4 at 2:03 AM | americanbankingnews.comAtyr PHARMA (ATYR) & Its Peers Critical ComparisonSeptember 7, 2024 | Investing Daily (Ad)These 2 simple sentences turn every Friday into payday?Most people have never heard of Jim Fink. Behind his humble demeanor and insistence on personal privacy... is a big secret. A trading strategy that has not taken a single loss this year. In fact, it has a 97% accuracy at closing out winners – for 8 years running.September 3, 2024 | americanbankingnews.comCritical Comparison: Atyr PHARMA (ATYR) and Its CompetitorsSeptember 2, 2024 | americanbankingnews.comComparing Atyr PHARMA (ATYR) & Its CompetitorsSeptember 2, 2024 | americanbankingnews.comCritical Comparison: Atyr PHARMA (ATYR) versus Its PeersAugust 30, 2024 | americanbankingnews.comReviewing Atyr PHARMA (NASDAQ:ATYR) & LianBio (NASDAQ:LIAN)August 21, 2024 | globenewswire.comaTyr Pharma to Participate in September Investor ConferencesSeptember 7, 2024 | Investing Daily (Ad)These 2 simple sentences turn every Friday into payday?Most people have never heard of Jim Fink. Behind his humble demeanor and insistence on personal privacy... is a big secret. A trading strategy that has not taken a single loss this year. In fact, it has a 97% accuracy at closing out winners – for 8 years running.August 18, 2024 | uk.finance.yahoo.comaTyr Pharma, Inc. (ATYR)August 15, 2024 | finance.yahoo.comIs aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?August 13, 2024 | globenewswire.comaTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate UpdateAugust 1, 2024 | markets.businessinsider.comaTyr Pharma’s Strategic Advances in Clinical Research Bolster Buy RatingSee More Headlines Receive ATYR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atyr PHARMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/06/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATYR Previous SymbolNASDAQ:ATYR CUSIPN/A CIK1339970 WebN/A Phone(858) 731-8389Fax858-731-8394Employees56Year FoundedN/APrice Target and Rating Average Stock Price Target$20.00 High Stock Price Target$35.00 Low Stock Price Target$9.00 Potential Upside/Downside+963.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,390,000.00 Net MarginsN/A Pretax Margin-9,846.26% Return on Equity-65.35% Return on Assets-49.81% Debt Debt-to-Equity Ratio0.01 Current Ratio7.63 Quick Ratio7.63 Sales & Book Value Annual Sales$588,000.00 Price / Sales220.65 Cash FlowN/A Price / Cash FlowN/A Book Value$1.07 per share Price / Book1.76Miscellaneous Outstanding Shares69,011,000Free Float66,458,000Market Cap$129.74 million OptionableOptionable Beta1.22 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Sanjay S. Shukla M.D. (Age 52)M.S., President, CEO & Director Comp: $768.18kMs. Jill M. Broadfoot (Age 62)Chief Financial Officer Comp: $544.75kMs. Nancy E. Denyes Krueger (Age 56)General Counsel & Corporate Secretary Comp: $518.2kXiang-Lei Yang Ph.D.FounderMs. Ashlee DunstonDirector of Investor Relations & Corporate CommunicationsMr. Peter VilligerVice President of Corporate DevelopmentMs. Danielle CampbellVP of Human ResourceDr. Leslie Nangle Ph.D.Vice President of ResearchDr. Ying J. Buechler Ph.D.Executive Director of Biologics Development & ManufacturingDr. David J. King Ph.D. (Age 65)Scientific Consultant Comp: $327.31kMore ExecutivesKey CompetitorsTerns PharmaceuticalsNASDAQ:TERNAnavex Life SciencesNASDAQ:AVXLVerve TherapeuticsNASDAQ:VERVSage TherapeuticsNASDAQ:SAGECOMPASS PathwaysNASDAQ:CMPSView All CompetitorsInsidersPaul SchimmelBought 52,300 shares on 7/24/2024Total: $100,939.00 ($1.93/share)Paul SchimmelBought 41,052 shares on 7/22/2024Total: $71,430.48 ($1.74/share)View All Insider Transactions ATYR Stock Analysis - Frequently Asked Questions How have ATYR shares performed this year? Atyr PHARMA's stock was trading at $1.74 at the start of the year. Since then, ATYR stock has increased by 8.0% and is now trading at $1.88. View the best growth stocks for 2024 here. How were Atyr PHARMA's earnings last quarter? Atyr PHARMA INC (NASDAQ:ATYR) posted its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. How do I buy shares of Atyr PHARMA? Shares of ATYR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATYR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredThese 2 simple sentences turn every Friday into payday?Most people have never heard of Jim Fink. Behind his humble demeanor and insistence on personal privacy... ...Investing Daily | SponsoredHere’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees n...Unstoppable Prosperity | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredLast Call for Crypto Summit (RSVP FREE)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And ...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atyr PHARMA INC Please log in to your account or sign up in order to add this asset to your watchlist. Share Atyr PHARMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
